^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Cholangiocarcinoma |
| Drug: | Imfinzi (durvalumab) (PD-L1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆
Excerpt:
The combination of cisplatin–gemcitabine with durvalumab should be considered in first-line BTC [I, A; ESMO-Magnitude of Clinical Benefit (MCBS) v1.1 score: 4.
